US 3D printer manufacturer 3D Systems has announced the formation of a new 3D bioprinting subsidiary.
Named Systemic Bio, the company is set to utilize the technologies developed as part of its parent firm’s Print to Perfusion program as well as those of its other subsidiary Allevi, to 3D bioprint vascularized organ models from human cells.
Backed with $15 million in seed funding from its owner, Systemic Bio now intends to market resulting tissues as a pharmaceutical drug discovery tool, with the aim of generating $100 million per year in revenue by 2027. These cells have already proven capable of accurately simulating human immune responses, and it’s thought they could help reduce drug R&D costs and lead times moving forwards.
“In forming Systemic Bio, we are applying these core technologies to specifically address critical needs within the pharmaceutical market,” said…
